Condition: Relapsed or Refractory Multiple Myeloma (RRMM) · Sponsor: Shandong New Time Pharmaceutical Co., LTD
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
This description comes directly from the study's public registry record.
Lu gui Qiu Doctor · （+86）13821266636 · Qiulg@ihcams.ac.cn
Shaohong Yin, Ext. · 15764210553 · yinshaohong@vip.lunan.cn
Always discuss trial participation with your own doctor first.
| Institute of Hematology & Blood Diseases Hospital | Tianjing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07579234